Comprehensive Cell Solutions @CCSNYBC

@CcsNybc

division of , supporting organizations advance & via NYBCe'S 50+ yrs of experience.

310 East 67th Street, NY, NY
Vrijeme pridruživanja: siječanj 2019.
Rođen/a 1. siječnja 1964.

Tweetovi

Blokirali ste korisnika/cu @CcsNybc

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @CcsNybc

  1. First human trial of monoclonal antibody to prevent opens. The phase I trial will give subjects mAb CIS43LS which may confer temporary immunity against the disease. This would be useful for travelers in endemic areas. Read more here ==>

    Poništi
  2. PACT Pharma strives to expand their manufacturing operations of products, raising $75 million in their Series C financing round. Read about how they plan to develop new cell therapies that target solid tumors ==>

    Poništi
  3. Results presented at the American Society of from a clinical trial show the experimental CS1001 proving effective at combating extranodal natural killer T-cell lymphoma () Learn about the immune checkpoint inhibitor here ==>

    Poništi
  4. Lab findings have prompted a clinical trial in which scientists strive to find out if can be used to bolster the effect of in . Listen to Dr. Joshua Brody talk about the possibilities of ==>

    Poništi
  5. Analysis of over 48,000 patients at MA General Hospital shows that age & sex may play a role in the optimal and deficient levels of iron in the blood. Find out what groups had a lower threshold for iron deficiency here ==>

    Poništi
  6. and have announced a collaboration to develop an natural killer T-cell therapy for the prevention and treatment of the 2019 Novel . Learn more about their plans for the CYNK-001 therapy ==>

    Poništi
  7. UVA Scientists state they have successfully used to treat age-related macular degeneration in mice. is the leading cause of vision loss in people older than 60. Find out how the scientists used the DICER1 enzyme to treat it ==>

    Poništi
  8. New In Mice Could Offer Lasting Protection Against Nerve Agents. Researchers arm mice with "bioscavengers" that seek and destroy nerve agents, granting immunity. Read how a liver enzyme could neutralize nerve agents like sarin ==>

    Poništi
  9. is currently developing a A , TAK-754, currently in phase I of clinical trials. Takeda’s head of R&D states he believes it likely won’t be a frontrunner in the market ==>

    Poništi
  10. According to St Jude Children’s Research Hospital and the Chinese Children’s Cancer Group, a phase III trial shows that plus is more effective at controlling than . Read the full study here ==>

    Poništi
  11. Biomaterial-based vaccine eliminates acute myeloid in mice. A solid vaccine made of and AML-specific antigens produced T-cell numbers 6X higher than traditional therapies. Read the Harvard researchers’ unexpected results ==>

    Poništi
  12. A case report of a man in France claims his rare IgE-producing developed into IgE-producing . The first sign of something awry was the detection of a kappa light chain monoclonal gammopathy. Read more here ==>

    Poništi
  13. In an early clinical trial, three patients who received autologous + cells engineered to promote production fared better than those who receive traditional therapies. Read the results presented at ASH’s annual meeting ==>

    Poništi
  14. Sets Gene Therapy Sights Beyond Hemophilia. In the wake of ’s price tag announcement, the Co. plans to begin human testing of for rare disorder . Read about their plans here ==>

    Poništi
  15. FDA Names Potential for Sickle Cell an ‘Orphan Drug.’ ARU-1801 stimulates the production of fetal hemoglobin instead of adult hemoglobin. Read what status means for the therapy here ==>

    Poništi
  16. New for Hemophilia A could be the most expensive drug ever. If FDA approved, Valrox from could cost $2-3 million per dose. This would be the 3rd gene therapy ever approved in the US. <--Hear what BioMarin’s chief has to say.

    Poništi
  17. A trending topic in the world and a must read: "How the Increased Need for Allogeneic Donors Could Impact Cell Therapy Research" Blog written by our medical director Patricia Shi, MD.

    Poništi
  18. FT-4202, experimental therapy, performs well in phase I of clinical trials. The drug activates PKR, which increases hemoglobin’s affinity to oxygen. Read the trial’s findings here ==>

    Poništi
  19. unveils new offerings from . “It becomes even more critical to find innovative ways to help our customers speed these transformational therapies to the patients who need them,” -Paul Kirchgraber. Learn more ==>

    Poništi
  20. Charles Hough suffered from most of his life. In 2018, scientists injected his own edited into his body & reduced his proportion of sickled cells from 97% to 37%. Hear Charles’s story of life after ==>

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·